BACKGROUND: Heightened immune activation and exhaustion drive HIV disease progression and comorbidities. Vitamin D has pleiotropic immunomodulatory effects, but little is known about the effects of supplementation in HIV. Our study investigates changes in immune activation and exhaustion markers after 12 months of supplementation in virologically suppressed HIV-infected youth with vitamin D insufficiency. METHODS: This is a randomized, active-control, double-blind trial investigating with three different vitamin D3 doses (18,000 [standard/active-control dose], 60,000 [moderate dose] and 120,000 IU/month [high dose]) in 8-25-year-old HIV-infected youth on combinationantiretroviral therapy with baseline serum 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/ml. Only subjects (n=51) who maintained an undetectable HIV-1 RNA over the 12-month study period were included in this analysis. RESULTS:Baseline serum 25(OH)D concentrations and immune activation/exhaustion markers were not different between groups. By 12 months, 25(OH)D increased significantly within each dosing group with the greatest increase and most sustained concentrations≥30 ng/ml in the high-dose group. Overall, all measured markers decreased with CD4 activation (CD4+CD38+HLA-DR+), CD8 activation (CD8+CD38+HLA-DR+), CD4 exhaustion (CD4+CD38+HLA-DR+PD1+) and inflammatory monocytes (CD14+CD16+) reaching statistical significance. When analysed separately, there were no significant decreases in the moderate- or standard-dose groups, but CD4 and CD8 activation and inflammatory monocytes decreased significantly in the high-dose group. CONCLUSIONS:Vitamin D supplementation decreased markers of T-cell activation/exhaustion and monocyte activation in HIV-infected youth, with subjects given the highest dose (120,000 IU/month) showing the greatest decreases. These data suggest that high-dose vitamin D supplementation may attenuate immune activation and exhaustion, and serve as adjuvant therapy to antiretroviral therapy in HIV. ClinicalTrials.gov identifier: NCT01523496.
RCT Entities:
BACKGROUND: Heightened immune activation and exhaustion drive HIV disease progression and comorbidities. Vitamin D has pleiotropic immunomodulatory effects, but little is known about the effects of supplementation in HIV. Our study investigates changes in immune activation and exhaustion markers after 12 months of supplementation in virologically suppressed HIV-infected youth with vitamin Dinsufficiency. METHODS: This is a randomized, active-control, double-blind trial investigating with three different vitamin D3 doses (18,000 [standard/active-control dose], 60,000 [moderate dose] and 120,000 IU/month [high dose]) in 8-25-year-old HIV-infected youth on combination antiretroviral therapy with baseline serum 25-hydroxyvitamin D (25(OH)D) concentrations ≤30 ng/ml. Only subjects (n=51) who maintained an undetectable HIV-1 RNA over the 12-month study period were included in this analysis. RESULTS: Baseline serum 25(OH)D concentrations and immune activation/exhaustion markers were not different between groups. By 12 months, 25(OH)D increased significantly within each dosing group with the greatest increase and most sustained concentrations ≥30 ng/ml in the high-dose group. Overall, all measured markers decreased with CD4 activation (CD4+CD38+HLA-DR+), CD8 activation (CD8+CD38+HLA-DR+), CD4 exhaustion (CD4+CD38+HLA-DR+PD1+) and inflammatory monocytes (CD14+CD16+) reaching statistical significance. When analysed separately, there were no significant decreases in the moderate- or standard-dose groups, but CD4 and CD8 activation and inflammatory monocytes decreased significantly in the high-dose group. CONCLUSIONS:Vitamin D supplementation decreased markers of T-cell activation/exhaustion and monocyte activation in HIV-infected youth, with subjects given the highest dose (120,000 IU/month) showing the greatest decreases. These data suggest that high-dose vitamin D supplementation may attenuate immune activation and exhaustion, and serve as adjuvant therapy to antiretroviral therapy in HIV. ClinicalTrials.gov identifier: NCT01523496.
Authors: Gary Hardiman; Stephen J Savage; E Starr Hazard; Robert C Wilson; Sean M Courtney; Michael T Smith; Bruce W Hollis; Chanita Hughes Halbert; Sebastiano Gattoni-Celli Journal: Pharmacogenomics Date: 2016-06-30 Impact factor: 2.533
Authors: Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver Journal: J Clin Endocrinol Metab Date: 2011-06-06 Impact factor: 5.958
Authors: Hooman Mirzakhani; Augusto A Litonjua; Thomas F McElrath; George O'Connor; Aviva Lee-Parritz; Ronald Iverson; George Macones; Robert C Strunk; Leonard B Bacharier; Robert Zeiger; Bruce W Hollis; Diane E Handy; Amitabh Sharma; Nancy Laranjo; Vincent Carey; Weilliang Qiu; Marc Santolini; Shikang Liu; Divya Chhabra; Daniel A Enquobahrie; Michelle A Williams; Joseph Loscalzo; Scott T Weiss Journal: J Clin Invest Date: 2016-11-14 Impact factor: 14.808
Authors: Mariam Aziz; Britt Livak; Jane Burke-Miller; Audrey L French; Marshall J Glesby; Anjali Sharma; Mary Young; Maria C Villacres; Phyllis C Tien; Elizabeth T Golub; Mardge H Cohen; Oluwatoyin M Adeyemi Journal: AIDS Date: 2013-02-20 Impact factor: 4.177
Authors: Saurabh Mehta; Edward Giovannucci; Ferdinand M Mugusi; Donna Spiegelman; Said Aboud; Ellen Hertzmark; Gernard I Msamanga; David Hunter; Wafaie W Fawzi Journal: PLoS One Date: 2010-01-19 Impact factor: 3.240
Authors: Christopher R Sudfeld; Ferdinand Mugusi; Alfa Muhihi; Said Aboud; Tumaini J Nagu; Nzovu Ulenga; Biling Hong; Molin Wang; Wafaie W Fawzi Journal: Lancet HIV Date: 2020-07 Impact factor: 12.767
Authors: Michael T Yin; Ellen S Chan; Todd T Brown; Jennifer Kinslow; Jeffrey Martinson; Alan Landay; Kathleen M Melbourne; Heather J Ribaudo; Edgar T Overton Journal: Antivir Ther Date: 2019
Authors: Sebastian Noe; Christine I Moeckel; Christiane Schwerdtfeger; Celia Oldenbuettel; Hans Jaeger; Eva Wolf; Christoph D Spinner Journal: Interdiscip Perspect Infect Dis Date: 2018-09-02